Glubiacombi Tablets 50/850 mg
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Hanol Biopharma Co., Ltd.
MFDS item code 201505860 · Approved 2015.08.20
This product's status changed to Approval withdrawn on 2023.12.18. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Improvement of glycemic control in type 2 diabetes mellitus
This medication is used in conjunction with diet and exercise to help control blood sugar in patients with type 2 diabetes. It can be used in individuals who have not previously taken diabetes medications or when sufficient blood glucose control is not achievable with monotherapy. Additionally, it can be used as a substitute or in combination when blood glucose control is inadequate with monotherapies of metformin or sitagliptin. If there is insufficient efficacy with the combination of metformin and sulfonylurea, or metformin and thiazolidinedione therapies, this medication can also be added. When blood glucose control is challenging under combinations of insulin and metformin, this medication can be used alongside to improve blood sugar levels. This medication effectively improves blood glucose control in various scenarios.
The dose of this drug for antidiabetic therapy should be determined based on each patient’s current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: sitagliptin 100 mg and metformin 2000 mg. This drug is generally taken twice daily with meals. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. The initial dose of this drug should be determined according to the patient’s current treatment regimen. 1. Patients not currently receiving metformin: For patients with no prior experience with antidiabetic drug therapy who do not achieve adequate glycemic control with monotherapy, or for whom adequate glycemic control cannot be achieved with sitagliptin monotherapy, the initial dose is 1 tablet of this drug 50/500 mg twice daily. The dose may be increased to 1 tablet of this drug 50/1000 mg twice daily. Patients with renal impairment who are receiving a reduced dose of sitagliptin should not be switched to this drug (see Precautions for Use, 2. Patients Who Must Not Be Given This Drug). 2. Patients receiving metformin: - For patients who do not achieve adequate glycemic control with metformin monotherapy, the recommended initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg) and the patient’s current metformin dose. - Patients switching from combination therapy with sitagliptin and metformin to this drug may start at their current doses of sitagliptin and metformin. 3. Patients who do not achieve adequate glycemic control with combination therapy of metformin and a sulfonylurea, metformin and insulin, or metformin and a thiazolidinedione: The initial dose of this drug is sitagliptin 50 mg twice daily (total daily dose 100 mg). The initial dose of metformin should take into account the patient’s blood glucose level and current dose. To reduce gastrointestinal adverse reactions caused by metformin, the dose should be increased gradually. When this drug is used in combination with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia induced by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). No studies have been conducted to evaluate the safety and efficacy of switching patients previously treated with other oral glucose-lowering drugs to this drug. Any change in the treatment regimen for type 2 diabetes may alter glycemic control; therefore, caution should be exercised and appropriate monitoring should be performed. Patients with renal impairment This drug may be used in patients with moderate renal impairment, stage 3a (creatinine clearance [CrCl] ≥ 45 and < 60 mL/min or estimated glomerular filtration rate (eGFR) ≥ 45 and < 60 mL/min/1.73m2), who do not have other conditions that may increase the risk of lactic acidosis, with the following dose adjustments. Since the starting dose of metformin is 500 mg or 850 mg once daily, treatment should not be initiated with this drug. The maximum recommended dose of metformin is 500 mg twice daily. Renal function should be monitored carefully every 3-6 months. If renal function declines to CrCl < 45 mL/min or eGFR < 45 mL/min/1.73m2, this drug should be discontinued immediately. Patients with hepatic impairment This drug should not be administered to patients with hepatic impairment because it contains metformin (see Precautions for Use, 2. Patients Who Must Not Be Given This Drug).
This medication contains two active components for the treatment of diabetes. The first component helps to control blood sugar but can rarely cause serious allergic reactions, so careful observation is necessary initially after administration. Moreover, this medication can induce pancreatitis, an inflammatory condition of the pancreas, so if symptoms like abdominal pain or vomiting occur during use, inform your physician immediately. The second component may pose risks for patients with renal impairment and should not be used in patients with severe renal dysfunction or in acute settings. This medication can cause serious side effects such as hypoglycemia and lactic acidosis, so special caution is required in situations like irregular meals, excessive exercise, or alcohol consumption. Additionally, it must be temporarily discontinued before certain tests or surgeries, and regular renal function assessments should be conducted. Women who are pregnant or breastfeeding, children under 18 years of age, and patients with specific heart or liver diseases should not take this medication. For the elderly, as the risk of renal function deterioration is higher, dose adjustments and regular kidney function tests are necessary. While using this medication, it may interact with other antidiabetic agents or specific medications; therefore, inform your physician or pharmacist about any medications being taken. Side effects may include diarrhea, headache, upper respiratory tract infections, and hypoglycemia; immediate consultation with healthcare professionals should occur if severe joint pain or skin rashes develop. In case of overdose, seek immediate medical attention for necessary treatment, as this medication may be partially removed by hemodialysis. Regular blood sugar checks and kidney function tests while using this medication are crucial to monitor health status continuously.
anaphylaxis
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a sealed container to prevent air exposure, ideally at temperatures between 1°C and 30°C. Storing it this way helps maintain the effectiveness of the medication.
Pink oval film-coated tablets
56 tablets (14 tablets/PTP*4)
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Sitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Hanol Biopharma Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Jongkun Dang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 1000mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationSitagliptin Phosphate Hydrate 64.25mg · Metformin Hydrochloride 850mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
CombinationMetformin Hydrochloride 500mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
Jong Kun Dang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 64.25mg
Tablet · Prescription medication · Combination
JongKeunDang Co., Ltd.
CombinationMetformin Hydrochloride 1000mg · Sitagliptin Phosphate Hydrate 128.5mg
Tablet · Prescription medication · Combination
Jongkundang Co., Ltd.
Sitagliptin Phosphate 62.04mg · Metformin Hydrochloride 500mg
Tablet · Prescription medication · Combination
Yuyu Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.